- Vir Biotechnology Inc VIR has amended the research collaboration agreement established with GSK plc GSK in 2020.
- Vir will continue its ongoing efforts to discover, develop and advance COVID-19 solutions and other potential coronavirus outbreaks, independently or with other partners.
- The companies will continue working to ensure ongoing access to sotrovimab for patients worldwide, where authorized, and to develop new therapies for influenza and other respiratory diseases.
- In August 2022, Vir and GSK said they do not plan to file a marketing application for sotrovimab for COVID-19, citing evolving COVID-19 landscape and FDA discussions.
- In April 2022, the FDA said the companies’ sotrovimab is no longer authorized to treat COVID-19 in any U.S. region due to increases in COVID-19 cases caused by the Omicron BA.2 sub-variant.
- In April 2020, GSK and Vir collaborated to research and develop solutions for coronaviruses.
- In 2021, the companies expanded their collaboration to include researching and developing new therapies for influenza and other respiratory viruses.
- Under the terms of the new amended agreement, Vir retains the sole rights to the solutions arising from the collaborative coronavirus vaccine and antibody programs, subject to tiered low- to mid-single-digit royalties to GSK.
- Price Action: VIR shares are down 1.53% at $25.78, and GSK shares are up 0.17% at $36.28 during the premarket session on the last check Tuesday.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
